Compare Manhattan Associates Inc (MANH) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Manhattan Associates Inc trades at $216.88 (market cap $12.99B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 11 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MANH | SYRE | |
|---|---|---|
Market Cap | $12.99B | $7.52B |
Volume | 546,880 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $223.76 | $108.92 |
52-Week Low | $120.88 | $22.18 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $12.85B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $222.71, up 2.21% today, with a bullish technical signal and strong profitability metrics including a 96.38% ROE. Recent earnings have consistently beaten expectations, and the company launched new Editions solutions to expand market access. However, high valuation ratios and a legal investigation pose headwinds.
The outlook remains positive with 80% analyst buy ratings and a $219.25 consensus target, but risks include elevated P/E of 63.81 and potential fiduciary breach concerns. Earnings growth and product innovation are key catalysts, yet investors should weigh valuation against legal and competitive pressures.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
